However, it has recently been discovered that mutations in some genes of NFκB platform result in constitutive activation of NFκB pathway making MM cells less dependent on BMME protection and more refractory to chemotherapy [56, 133, 134]. Here, NFKB1 is linked to Miyoshi myopathy.